Eli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow LLY
Eli Lilly and Company (LLY) Return on invested capital
Eli Lilly and Company's return on invested capital over the twelve months to 30 June 2026 was 26.3%, down 1.0 percentage points from fiscal 2025 (27.3%). Over the past ten years it has ranged from 7.25% (fiscal 2017) to 27.3% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 6.11% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 27.3% | 6.95 |
| FY2024 | 20.4% | 5.02 |
| FY2023 | 15.4% | (3.75) |
| FY2022 | 19.1% | (0.17) |
| FY2021 | 19.3% | (0.91) |
| FY2020 | 20.2% | 0.40 |
| FY2019 | 19.8% | 3.79 |
| FY2018 | 16.0% | 8.76 |
| FY2017 | 7.25% | (3.86) |
| FY2016 | 11.1% | 1.83 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| LLY Eli Lilly and Company | 26.3% |
| ABBV AbbVie Inc. compare | 18.1% |
| NVS Novartis AG compare | 13.1% |
| AMGN Amgen Inc. compare | 13.0% |
| AZN AstraZeneca PLC compare | 11.7% |
| PFE Pfizer Inc. compare | 6.30% |
| MRK Merck & Co., Inc. compare | 5.08% |
| JNJ Johnson & Johnson compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −4.48% |
| Drug Manufacturers General industry median | 6.11% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on LLY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement